8
VogelsteinScience15Apr13.ppt Updated: April 15, 2013 Why Is Cancer Therapy Such a Difficult and Often Intractable Effort? Cancer Genome Landscapes. Science, Vol. 339, March 29, 2013, pp 1546 – 1548 Bert Vogelstein, Nickolas Papadopoulos, Victor Velculescu, Shibin Zhou, Luis Diaz, Kenneth W. Kinzler Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore

VogelsteinScience15Apr13 Updated: April 15, 2013

Embed Size (px)

DESCRIPTION

Why Is Cancer Therapy Such a Difficult and Often Intractable Effort?. Cancer Genome Landscapes. Science, Vol. 339, March 29, 2013, pp 1546 – 1548 Bert Vogelstein, Nickolas Papadopoulos, Victor Velculescu, Shibin Zhou, Luis Diaz, Kenneth W. Kinzler - PowerPoint PPT Presentation

Citation preview

Page 1: VogelsteinScience15Apr13 Updated: April 15, 2013

VogelsteinScience15Apr13.pptUpdated: April 15, 2013

Why Is Cancer Therapy Such a Difficult and Often Intractable Effort?

Cancer Genome Landscapes.

Science, Vol. 339, March 29, 2013, pp 1546 – 1548

Bert Vogelstein, Nickolas Papadopoulos, Victor Velculescu, Shibin Zhou, Luis Diaz, Kenneth W. Kinzler

Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore

Page 2: VogelsteinScience15Apr13 Updated: April 15, 2013

Number of somatic mutations associated with cancers in patients

Page 3: VogelsteinScience15Apr13 Updated: April 15, 2013

From 5 or 10 to 130 to 700

mutations per tumor

Page 4: VogelsteinScience15Apr13 Updated: April 15, 2013

(Insertions & deletions)

(Single base substitutions)

Page 5: VogelsteinScience15Apr13 Updated: April 15, 2013
Page 6: VogelsteinScience15Apr13 Updated: April 15, 2013

SignalingPathwaysAffectedIn Cancers

Page 7: VogelsteinScience15Apr13 Updated: April 15, 2013

Pathway Anomalies in Progression in Colo-Rectal Cancer

Page 8: VogelsteinScience15Apr13 Updated: April 15, 2013

The RAS Pathway as a representative signaling pathway affected by cancer

mutations and approaches to

therapy based on RAS pathway

anomalies

RTK = receptor tyrosine kinase